Literature DB >> 28815922

The pregnancy in neurofibromatosis 1: A retrospective register-based total population study.

Jussi Leppävirta1,2, Roope A Kallionpää1, Elina Uusitalo1, Tero Vahlberg1,2, Minna Pöyhönen3,4, Susanna Timonen1,2, Juha Peltonen1, Sirkku Peltonen1,2.   

Abstract

The objective of this retrospective total population study was to form a view of the pregnancies of the patients with neurofibromatosis type 1 (NF1). A cohort of 1,410 Finnish patients with NF1 was acquired by searching NF1-related inpatient and outpatient hospital visits and confirming the diagnoses by reviewing the medical records. Ten matched control persons per patient with NF1 were collected from Population Register Centre. Study persons were linked to data from Medical Birth Register and Care Register for Health Care through the personal identity code. Cesarean deliveries, hypertension/preeclampsia, and placental abruptions were more common among mothers with NF1 with adjusted odds ratios of 2.24 (95%CI 1.63-3.07), 1.96 (95%CI 1.18-3.24), and 13.40 (95%CI 4.26-42.13), respectively. The adjusted mean pregnancy duration was 0.65 (95%CI 0.42-0.88) weeks shorter among the mothers with NF1 than in the control group consisting of non-NF1 mothers giving birth to a non-NF1 child. The pregnancies of non-NF1 mothers giving birth to a NF1 child were 0.43 (95%CI 0.24-0.62) weeks shorter than in the control group. In summary, NF1 of the mother was associated with a shortened pregnancy and increased pregnancy complications. Also, the NF1 of the fetus slightly shortened pregnancy. Since mothers with NF1 are at increased risk for pregnancy complications, careful evaluation of their pregnancies is warranted.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  delivery complications; neurofibromatosis type 1; pregnancy complication; pregnancy duration

Mesh:

Year:  2017        PMID: 28815922     DOI: 10.1002/ajmg.a.38372

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012.

Authors:  Takashi Yamauchi; Machi Suka; Chikako Nishigori; Hiroyuki Yanagisawa
Journal:  Orphanet J Rare Dis       Date:  2019-07-05       Impact factor: 4.123

2.  Neurofibromatosis type 1 of the child increases birth weight.

Authors:  Jussi Leppävirta; Roope A Kallionpää; Elina Uusitalo; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  Am J Med Genet A       Date:  2019-04-24       Impact factor: 2.802

3.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

Review 4.  Fatal maternal complication due to neurofibromatosis type 1-associated giant pigmented plexiform neurofibromas in pregnancy: a case report and literature review.

Authors:  Leo Odongo; Matthias Goebeler; Hermann Kneitz; John C Lule; Godwin Turyasingura
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

5.  Cohort profile: life with neurofibromatosis 1 - the Danish NF1 cohort.

Authors:  Karoline Doser; Hanne Hove; John R Østergaard; Pernille E Bidstrup; Susanne O Dalton; Mette Møller Handrup; Cecilie Ejerskov; Anja Krøyer; Mia Aagaard Doherty; Jens Richardt Møllegaard Jepsen; John J Mulvihill; Jeanette F Winther; Line Kenborg
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

6.  Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study.

Authors:  Jussi Leppävirta; Roope A Kallionpää; Elina Uusitalo; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  Orphanet J Rare Dis       Date:  2018-01-15       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.